

**Gefarnil : systemic healing in gastric and duodenal ulcers.**

**Contributors**

The Crookes Laboratories Limited

**Publication/Creation**

1971.

**Persistent URL**

<https://wellcomecollection.org/works/mgx4zm2d>

**License and attribution**

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).

**wellcome  
collection**

Wellcome Collection  
183 Euston Road  
London NW1 2BE UK  
T +44 (0)20 7611 8722  
E [library@wellcomecollection.org](mailto:library@wellcomecollection.org)  
<https://wellcomecollection.org>

# Gefarnil<sup>®</sup>



**Systemic healing in gastric  
and duodenal ulcers**

60 days treatment . . .  
The relief of a lifetime

The CROOKES Laboratories Limited  
Basingstoke Hampshire

# Gefarnil


Gefarnate

- Indications**      Gastric ulcer, duodenal ulcer,  
Gastro duodenitis
- Daily Dosage**    Oral: 1 capsule 4 times daily,  $\frac{1}{2}$  hr  
before meals for 60 days.  
I.M. 2 ampoules per day in divided  
doses.
- Note**                Gefarnil acts systemically to produce  
a regenerative and protective action  
on the gastric and duodenal mucosa.  
It should be noted that this systemic  
healing process cannot be expected  
to give immediate symptomatic relief  
and several days treatment with  
Gefarnil may be necessary before  
the ulcer healing has reached a stage  
where symptomatic treatment of the  
conventional kind can be  
discontinued.
- Side Effects**      Side effects such as electrolyte  
disturbances, hypertension or  
oedema do not occur with Gefarnil.  
Slight urticarial rash has been  
reported on very rare occasions.
- Contra indications**    None known.
- Presentation**      Bottle of 100 capsules each capsule  
containing 50mg gefarnate.  
Box of 6 x 1ml ampoules, each  
ampoule containing 50 mg gefarnate.

**Gefarnil**

Recent evidence from an interim report of a British double blind trial\* confirms the healing effect of Gefarnil.

Results in 23 gastric ulcer patients.



All patients were treated on an outpatient basis. There were no dietary or other restrictions except instructions to avoid fried food. All patients were allowed antacids, when required, to relieve pain.

\*Report 4th World Congress of Gastroenterology.

# Gefarnil®

Further information is available on request.

® Gefarnil is a trade mark and is manufactured under licence from Istituto De Angeli, Milan, Italy

by The CROOKES Laboratories Limited  
Basingstoke Hampshire

GEF/AUG/71/R